Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
   
Ask the Experts About

Hepatitis and HIV CoinfectionHepatitis and HIV Coinfection
           
Rollover images to visit our other forums!
Recent AnswersAsk a Question
  
  • Email Email
  • Glossary Glossary


Insulin Resistant Hep-c geno type 1
Jul 4, 2007

I took the Peleged Iterferon Ribavirin a few years ago weekly injections and was never completely healed. know my Dr. wants me to take a pilot trial combination with Interferon Alfacon-1, Ribavirin, and Rosiglitazone. I not sure if I should since they can't give me a percent of cure What are your thoughts.

Ken

Response from Dr. McGovern

I would definitely consider it. There are emerging data that suggest that patients with insulin resistance (IR) do not respond to HCV treatment as well as patients who do not have IR. This is the rationale to try combination therapy with rosiglitazone, which treats IR.

I am sure that they will check your viral load response after 4 and 12 weeks and by then you will already know your chances of a response.

Best of luck.



Previous
Hepatitis B
Next
hbv and pregnancy

  
  • Email Email
  • Glossary Glossary

 Get Email Notifications When This Forum Updates or Subscribe With RSS


 
Advertisement



Q&A TERMS OF USE

This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint

Advertisement